Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz as second-line monotherapy in advanced pancreatic adenocarcinoma
2008-004273-18Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Institut Bergonié. Primary endpoint: Non-morphological progression at 2 months. Started Oct 2008; status: completed.
02
Drugs
efavirenz
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2008-004273-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004273-18.